Research Papers:

An explorative analysis of the prognostic value of lactate dehydrogenase for survival and the chemotherapeutic response in patients with advanced triple-negative breast cancer

Zhenya Jia _, Jian Zhang, Zhonghua Wang, Biyun Wang, Leiping Wang, Jun Cao, Zhonghua Tao and Xichun Hu

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:10714-10722. https://doi.org/10.18632/oncotarget.24246

Metrics: PDF 1280 views  |   HTML 2860 views  |   ?  


Zhenya Jia1,2,*, Jian Zhang1,*, Zhonghua Wang1, Biyun Wang1, Leiping Wang1, Jun Cao1, Zhonghua Tao1 and Xichun Hu1

1Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

2Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei 230032, China

*These authors contributed equally to this work

Correspondence to:

Jian Zhang, email: [email protected]

Xichun Hu, email: [email protected]

Keywords: triple-negative breast cancer; lactate dehydrogenase; metastasis; prognosis

Received: November 18, 2016     Accepted: December 05, 2017     Published: January 13, 2018


Serum lactate dehydrogenase (LDH) level is predictive of prognosis in various malignancies. Nevertheless, the association between the prognosis of patients with advanced triple-negative breast cancer (TNBC) and LDH is not well understood. This explorative and retrospective study was conducted to clarify the issue. We found that abnormal baseline LDH levels (> 250 IU/L) were significantly associated with age (> 40 y vs. ≤ 40 y, OR: 0.383, P = 0.031) and number of metastatic sites (2 vs. 1, OR: 4.619, P = 0.006; ≥ 3 vs. 1, OR: 4.727, P = 0.002). The progression-free survival (PFS) of patients with post-treatment LDH higher than baseline (Group 1) was significantly shorter than that in patients with LDH decreased to normal (Group 3) and those with normal baseline and post-treatment LDH (Group 4) (Group 3 vs. Group 1, HR: 0.517, P = 0.038; Group 4 vs. Group 1, HR: 0.346, P < 0.001). Overall survival (OS) in patients with abnormal baseline LDH was significantly shorter than in patients with normal baseline LDH (abnormal vs. normal, HR: 2.073, P < 0.001). Patients whose post-treatment LDH decreased to normal had the most objective response (complete and partial responses) rate after first-line chemotherapy (Group 3 vs. Group 1, OR: 0.074, P < 0.001). In this exploratory analysis, baseline LDH levels associated with OS, while LDH changes after first-line chemotherapy associated with PFS and the chemotherapeutic response. These results show that LDH may have important prognostic value for the survival and chemotherapeutic response in patients with advanced TNBC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24246